Dr. Singal on the FDA Approval of Durvalumab With Tremelimumab in Unresectable HCC
Amit Singal, MD, discusses the FDA approval of durvalumab with tremelimumab (Imjudo) in unresectable hepatocellular carcinoma.
Dr. Kim on The Evaluation of TKI/Immunotherapy Combos in HCC
Richard Kim, MD, discusses the evaluation of TKI and immunotherapy combination regimens in hepatocellular carcinoma.
Dr. Shroff on the Utility of the HIMALAYA Regimen in HCC
Rachna T. Shroff, MD, MS, discusses the utility of combining anti–CTLA-4 and anti–PD-1 therapies in hepatocellular carcinoma.
Dr. Abou-Alfa on Areas Ripe for Further Exploration in HCC
Ghassan K. Abou-Alfa, MD, discusses areas ripe for further exploration in hepatocellular carcinoma.
Dr. Abou-Alfa on Analyzing Disease Factors to Inform Clinical Decisions in HCC
Ghassan K. Abou-Alfa, MD, discusses the analysis of disease and patient factors to inform clinical decisions in hepatocellular carcinoma.
Dr. Goff on Leveraging Clinical Trial Information to Inform Treatment Decisions in HCC
Laura Goff, MD, discusses how to consider clinical trial information to inform treatment decisions in patients with hepatocellular carcinoma.
Dr. Shroff on Remaining Unmet Needs for Patients With HCC
Rachna T. Shroff, MD, MS, discusses remaining unmet needs for patients with hepatocellular carcinoma.
Dr. Kim on the Evolution of Frontline Treatment in HCC
Richard Kim, MD, discusses the evolution of frontline treatment in hepatocellular carcinoma.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512